XL844

DRUG2 trials

Sponsors

Exelixis

Conditions

CancerChronic Lymphocytic LeukemiaLymphomaSmall Lymphocytic Lymphoma

Phase 1

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

TerminatedNCT00234481

ExelixisChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Updated: 2008-06-04

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

TerminatedNCT00475917

ExelixisCancer, Lymphoma

Start: 2007-05-31End: 2008-12-31Updated: 2015-08-21